| Income Statement | 2025-09-30 | 2024-09-30 | 2024-06-30 | 2024-03-31 |
|---|---|---|---|---|
| Selling and marketing expense | - | - | 5,000 | - |
| General and administrative expenses | - | 173,073 | 239,028 | 269,456 |
| Share based compensation | - | 96,888 | 611,570 | - |
| Professional services expense | - | 431,304 | 864,588 | 1,180,499 |
| Amortization expense | - | 250,000 | 250,000 | 250,000 |
| Salary expense | - | 378,740 | 459,099 | 445,359 |
| Research and development expense | - | 811,784 | 398,817 | 777,069 |
| Operating expenses | - | 2,141,789 | 2,828,102 | 2,922,383 |
| Operating income (loss) | - | -2,141,789 | -2,828,102 | -2,922,383 |
| Change in fair value of derivative liability warrants | - | 349,500 | -149,250 | 34,875 |
| Disposal group, not discontinued operation, loss (gain) on write-down | - | 37,257 | - | - |
| Other income (expense) | - | 51,558 | 8,063 | 86,625 |
| Interest expense | - | - | 66,056 | - |
| Interest expense, nonoperating | - | 50,926 | - | 200,505 |
| Nonoperating income (expense) | - | 312,875 | -207,243 | -79,005 |
| Provision for income taxes | 0 | - | - | - |
| Income (loss) from continuing operations before income taxes, noncontrolling interest | - | -1,828,914 | -3,035,345 | -3,001,388 |
| Net loss attributable to common stockholders | -2,739,403 | - | - | - |
| Net income (loss), including portion attributable to noncontrolling interest | - | -1,828,914 | -3,035,345 | - |
| Net loss attributable to non-controlling interests | 159,360 | - | - | - |
| Net loss | -2,898,763 | -1,828,914 | -3,035,345 | -3,001,388 |
| Loss per share, basic | -0.58 | -0.05 | -0.08 | -0.08 |
| Loss per share, fully diluted | -0.58 | -0.05 | -0.08 | -0.08 |
| Weighted average number of common shares outstanding, basic | 4,745,089 | 39,806,505 | 37,569,312 | 35,544,709 |
| Weighted average number of common shares outstanding, diluted | 4,745,089 | 39,806,505 | 37,569,312 | 35,544,709 |
Coeptis Therapeutics Holdings, Inc. (COEP)
Coeptis Therapeutics Holdings, Inc. (COEP)